In a randomized controlled trial conducted by Brian A. Bergmark et al. involving a substantial cohort of patients with acute coronary syndrome (ACS), higher FGF23 concentration was associated with an increased risk of severe cardiovascular events, such as cardiovascular mortality or hospitalization due to heart failure. Here, FGF23 is linked to heart failure.